NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
PCRX
Pacira BioSciences, Inc.
PCRX has the edge over NVO overall, supported by stronger valuation and stronger fundamentals.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
PCRX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Strong | |
| Strong |
PCRX's profitability, cash flow and balance sheet are currently healthy. There isn't enough data to rate its revenue.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over PCRX in the historical PE scenario, which offers more potential upside but is not a forecast.
PCRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 11x | $36.46 | — |
| Cheap | 19x | $17.40 | -52% |
| Current | 39x | $36.46 | — |
| Fair | 59x | $55.10 | +51% |
| Expensive | 166x | $156 | +328% |
Historical ranges are pointers, not guarantees.
PCRX's PE is in its fair range at 39x. If earnings grow as analysts expect, today's price would be 11x next year's earnings, in its cheap range.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
PCRX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect PCRX's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over PCRX on earnings, with more consistent year-over-year improvement.
PCRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.23 | +244% |
| Q3 2026 | $0.94 | +92% |
| Q2 2026 | $0.36 | +$3.10 |
| Q1 2026 | $0.13 | +$2.37 |
| Q4 2025 | $0.16 | +$2.31 |
| Q3 2025 | $0.49 | +$2.44 |
| Q2 2025 | -$2.74 | -297% |
| Q1 2025 | -$2.24 | -248% |
| Q4 2024 | -$2.15 | -342% |
PCRX's earnings per share have fallen from their peak: $0.94 over the past year, against $3.91 in mid-2021.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over PCRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over PCRX on profitability, with a higher operating margin.
PCRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $176.7M | -1.6% |
| Q2 2026 | $192.4M | +6.2% |
| Q1 2026 | $177.4M | +5% |
| Q3 2025 | $179.5M | +6.5% |
| Q2 2025 | $181.1M | +1.7% |
| Q1 2025 | $168.9M | +1.1% |
| Q3 2024 | $168.6M | +2.8% |
| Q2 2024 | $178M | +5% |
PCRX's revenue has picked up after two years of holding roughly level: $177M last quarter, down 1.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | +9.1 points |
| Q2 2026 | 2.2% | -2.5 points |
| Q1 2026 | 3.9% | +2.7 points |
| Q4 2025 | 1.2% | N/A |
| Q3 2025 | 3.5% | +86 points |
| Q2 2025 | 4.7% | -11 points |
| Q1 2025 | 1.2% | -6.7 points |
| Q3 2024 | -83% | -94 points |
PCRX's operating margin was 13% last quarter, up 9.1 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over PCRX on cash flow, with more consistent year-over-year improvement.
PCRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $46.4M | -18% |
| Q2 2026 | $56.1M | +503% |
| Q1 2026 | $23M | -15% |
| Q4 2025 | $43.5M | +40% |
| Q3 2025 | $57M | +14% |
| Q2 2025 | $9.3M | -82% |
| Q1 2025 | $26.9M | -42% |
| Q4 2024 | $31M | -32% |
PCRX generated $169M in free cash flow over the past year, up 36% from the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
PCRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +530K shares |
| 1 year | -8.2% | -3.6M shares |
| 3 years | -22% | -11.2M shares |
| 5 years | -10% | -4.6M shares |
| Available history | -1.6% | -683K shares |
PCRX has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $50M |
| Q4 2025 | $48.2M |
| Q3 2025 | $50M |
| Q4 2024 | — |
| Q3 2024 | — |
PCRX spent $98M buying back its own shares over the past year.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
PCRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.4x | Very low |
| Q2 2026 | 1.5x | Healthy |
| Q1 2026 | 1.9x | Healthy |
| Q4 2025 | 1.9x | Healthy |
| Q3 2025 | 1.7x | Healthy |
| Q4 2024 | 57.0x | High |
| Q3 2024 | -22.1x | Net Cash |
| Q2 2024 | -1.5x | Net Cash |
PCRX has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
PCRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 77.6 | Overbought |
| Stochastic | 98.3 | Overbought |
PCRX's weekly RSI is 78 (overbought) and its Stochastic is 98 (overbought).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over PCRX on valuation relative to its sector.
PCRX PE vs Healthcare Sector
| Metric | PCRX | Sector median | Relative |
|---|---|---|---|
| PE | 39x | 26x | 50% above |
| PE % | 37 | 29 | 8 pts above |
PCRX is trading at 39x earnings, a 50% premium to the Healthcare sector's median of 26x.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
PCRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $33.6 | 8.5% above |
| 20 week MA | $28.6 | 27% above |
| 50 week MA | $25.4 | 44% above |
| 100 week MA | $24.7 | 48% above |
| 200 week MA | $27.3 | 33% above |
PCRX has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
PCRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.6 | $59.2 | +33% |
| 2021 | $59.2 | $61.7 | +4.1% |
| 2022 | $61.7 | $39.7 | -36% |
| 2023 | $39.7 | $33.7 | -15% |
| 2024 | $33.7 | $19.7 | -42% |
| 2025 | $19.7 | $26.5 | +35% |
| 2026 YTD | $26.5 | $36.5 | +38% |
PCRX has the edge over NVO on returns for 2026, with the stronger performance.